Document Detail

The role of antisense oligonucleotides in the treatment of bladder cancer.
MedLine Citation:
PMID:  12111175     Owner:  NLM     Status:  MEDLINE    
Both intravesical and systemic chemotherapy are limited in their efficacy in the treatment of bladder cancer patients. These limitations are centred around an inability to induce apoptosis in bladder tumour cells. This resistance to apoptosis induction is commonly associated with the overexpression of antiapoptotic proteins such as Bcl-2. Strategies to decrease the cellular expression of such proteins would enhance chemotherapy effectiveness. One such strategy is to use antisense oligonucleotides which are short sequence specific single stranded DNA or RNA molecules designed to bind to the RNA of the target protein. By binding to the target RNA, protein production is interrupted and target protein levels decease. When used to target antiapoptotic proteins, antisense oligonucleotides can therefore be used as a pre-treatment before chemotherapy to help chemosensitise the tumour cell. This review outlines the rationale for this strategy and the work done to date with antisense oligonucleotides in bladder cancer.
Brian J Duggan; Sam Gray; Samuel R Johnston; Kate Williamson; Hideaki Miyaki; Martin Gleave
Related Documents :
8031825 - A functional superfamily of sodium/solute symporters.
18790835 - Bnip3 functions as a mitochondrial sensor of oxidative stress during myocardial ischemi...
15682435 - Lack of bcl-2 expression in follicular lymphoma may be caused by mutations in the bcl2 ...
15342605 - Recombinant cyclophilins lack nuclease activity.
7693735 - Chicken filensin: a lens fiber cell protein that exhibits sequence similarity to interm...
11058095 - Involvement of rb family proteins, focal adhesion proteins and protein synthesis in sen...
Publication Detail:
Type:  Journal Article; Review     Date:  2002-05-23
Journal Detail:
Title:  Urological research     Volume:  30     ISSN:  0300-5623     ISO Abbreviation:  Urol. Res.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-11     Completed Date:  2003-01-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0364311     Medline TA:  Urol Res     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  137-47     Citation Subset:  IM    
Department of Urology and Quantitative Pathology, Belfast City Hospital, Belfast, BT12 6BL, Northern Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Designer Drugs
Genes, bcl-2 / genetics
Oligonucleotides, Antisense / adverse effects,  genetics,  pharmacokinetics,  therapeutic use*
Structure-Activity Relationship
Treatment Failure
Urinary Bladder Neoplasms / drug therapy*,  physiopathology,  therapy
Reg. No./Substance:
0/Designer Drugs; 0/Oligonucleotides, Antisense

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nickel accumulation and nickel oxalate precipitation by Aspergillus niger.
Next Document:  New method: the intravital videomicroscopic characteristics of the microcirculation of the urinary b...